ImmunoGen, Inc. Profile Avatar - Palmy Investing

ImmunoGen, Inc.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase…
Biotechnology
US, Waltham [HQ]
Government, Law & Regulation

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

ImmunoGen, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
0.0 IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
YoY Trends
  • No trends presentable at the moment.

Spending By Type

Awards
Obligations
Contracts IDV Contracts Grants Loans Direct Other

ImmunoGen, Inc. can't present spending by time.

Contract Analysis

There are no contract award details available for ImmunoGen, Inc.

End of IMGN's Analysis
CIK: 855654 CUSIP: 45253H101 ISIN: US45253H1014 LEI: - UEI: -
Secondary Listings